A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19

Summary

The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of Care (SOC).

Timeline

Start

2022-01-15

Primary completion

2022-12-01

Completion

2022-12-01

Outcome

Outcome not reported

Stopped: “The study was withdraw due to the fast spread of Omicron variant worldwide”

Drugs

Indications